In the STELLAR clinical trial, rosuvastatin at doses ranging from 10 mg to 40 mg was reported to be superior compared to other statins in improving the lipid profile in subjects with hypercholesterolemia, including ApoB levels. This evidence concerns the gene APOB and familial hypercholesterolemia.